CMMB - Chemomab Therapeutics to Participate in Upcoming Scientific Conferences | Benzinga
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver.
The presentations cover a range of topics, from new preclinical studies further elucidating the roles of the soluble protein target CCL24 and Chemomab's CCL24 neutralizing antibody CM-101 in fibro-inflammatory disease, to novel translational research designed to support the ongoing clinical development of CM-101 for primary sclerosing cholangitis, a rare and often fatal fibrotic liver disease. The presentations will be made available and described in greater detail post embargo.
Gordon Research Conference: Chemotactic Cytokines - Portland, Maine, USA, June 2-7, 2024
| Date: |
| June 2-7, 2024 |
| Format: |
| Poster presentation: Attenuating liver fibrosis and inflammation: ... |